within Pharmacolibrary.Drugs.ATC.M;

model M05BX06
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.833333333333334e-06,
    adminDuration  = 600,
    adminMass      = 210 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00392,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00273,
    k12             = 0.292,
    k21             = 0.292
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BX06</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Romosozumab is a monoclonal antibody that inhibits sclerostin, thereby stimulating bone formation and decreasing bone resorption. It is used for the treatment of osteoporosis in postmenopausal women at high risk of fracture, and is an approved medication in several countries including the US, EU, and Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in postmenopausal women with osteoporosis following the approved subcutaneous regimen of 210 mg once monthly.</p><h4>References</h4><ol><li><p>Bandeira, L, et al., &amp; Bilezikian, JP (2017). Romosozumab for the treatment of osteoporosis. <i>Expert opinion on biological therapy</i> 17(2) 255–263. DOI:<a href=\"https://doi.org/10.1080/14712598.2017.1280455\">10.1080/14712598.2017.1280455</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28064540/\">https://pubmed.ncbi.nlm.nih.gov/28064540</a></p></li><li><p>Paik, J, &amp; Scott, LJ (2020). Romosozumab: A Review in Postmenopausal Osteoporosis. <i>Drugs &amp; aging</i> 37(11) 845–855. DOI:<a href=\"https://doi.org/10.1007/s40266-020-00793-8\">10.1007/s40266-020-00793-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32909197/\">https://pubmed.ncbi.nlm.nih.gov/32909197</a></p></li><li><p>Hsu, CP, et al., &amp; Yu, Z (2022). Influence of Renal Function on Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Romosozumab. <i>Journal of clinical pharmacology</i> 62(9) 1132–1141. DOI:<a href=\"https://doi.org/10.1002/jcph.2050\">10.1002/jcph.2050</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35304747/\">https://pubmed.ncbi.nlm.nih.gov/35304747</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BX06;
